Prostate cancer with neuroendocrine differentiation - Revision history

Michael: /* IHC */

2018-03-19T22:47:52Z

IHC

← Older revision		Revision as of 22:47, 19 March 2018
Line 16:		Line 16:

	==IHC==		==IHC==
	*[[PSA]] typically negative in ~~NE carcinoma~~.		*[[PSA]] typically negative in neuroendocrine carcinomas.

	==See also==		==See also==

Michael: /* See also */

2018-03-19T22:47:22Z

Michael at 16:34, 19 March 2018

2018-03-19T16:34:59Z

← Older revision		Revision as of 16:34, 19 March 2018
Line 2:		Line 2:

	'''Neuroendocrine carcinoma of the prostate''' redirect here.		'''Neuroendocrine carcinoma of the prostate''' redirect here.

			==General==
			*Treatment: platinum based therapy.

	==Subclassification==		==Subclassification==

Michael: tweak

2018-03-19T16:31:40Z

tweak

← Older revision		Revision as of 16:31, 19 March 2018
Line 1:		Line 1:
	'''~~Neuroendocrine carcinoma of the prostate~~''' is a rare group of [[prostate cancer]]s that is hypothesized to evolve in the context androgen deprivation therapy.<ref name=pmid24705311>{{Cite journal \| last1 = Epstein \| first1 = JI. \| last2 = Amin \| first2 = MB. \| last3 = Beltran \| first3 = H. \| last4 = Lotan \| first4 = TL. \| last5 = Mosquera \| first5 = JM. \| last6 = Reuter \| first6 = VE. \| last7 = Robinson \| first7 = BD. \| last8 = Troncoso \| first8 = P. \| last9 = Rubin \| first9 = MA. \| title = Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. \| journal = Am J Surg Pathol \| volume = 38 \| issue = 6 \| pages = 756-67 \| month = Jun \| year = 2014 \| doi = 10.1097/PAS.0000000000000208 \| PMID = 24705311 }}</ref>		'''Prostate cancer with neuroendocrine differentiation''' is a rare group of [[prostate cancer]]s that is hypothesized to evolve in the context androgen deprivation therapy.<ref name=pmid24705311>{{Cite journal \| last1 = Epstein \| first1 = JI. \| last2 = Amin \| first2 = MB. \| last3 = Beltran \| first3 = H. \| last4 = Lotan \| first4 = TL. \| last5 = Mosquera \| first5 = JM. \| last6 = Reuter \| first6 = VE. \| last7 = Robinson \| first7 = BD. \| last8 = Troncoso \| first8 = P. \| last9 = Rubin \| first9 = MA. \| title = Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. \| journal = Am J Surg Pathol \| volume = 38 \| issue = 6 \| pages = 756-67 \| month = Jun \| year = 2014 \| doi = 10.1097/PAS.0000000000000208 \| PMID = 24705311 }}</ref>

			'''Neuroendocrine carcinoma of the prostate''' redirect here.

			==Subclassification==
	It is subclassified as per Epstein ''et al.'':<ref name=pmid24705311/>		It is subclassified as per Epstein ''et al.'':<ref name=pmid24705311/>
	*Usual prostate adenocarcinoma with neuroendocrine differentiation.		*Usual prostate adenocarcinoma with neuroendocrine differentiation.

Michael: split out

2018-03-19T16:29:58Z

split out

New page

'''Neuroendocrine carcinoma of the prostate''' is a rare group of [[prostate cancer]]s that is hypothesized to evolve in the context androgen deprivation therapy.<ref name=pmid24705311>{{Cite journal | last1 = Epstein | first1 = JI. | last2 = Amin | first2 = MB. | last3 = Beltran | first3 = H. | last4 = Lotan | first4 = TL. | last5 = Mosquera | first5 = JM. | last6 = Reuter | first6 = VE. | last7 = Robinson | first7 = BD. | last8 = Troncoso | first8 = P. | last9 = Rubin | first9 = MA. | title = Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. | journal = Am J Surg Pathol | volume = 38 | issue = 6 | pages = 756-67 | month = Jun | year = 2014 | doi = 10.1097/PAS.0000000000000208 | PMID = 24705311 }}</ref>

It is subclassified as per Epstein ''et al.'':<ref name=pmid24705311/>
*Usual prostate adenocarcinoma with neuroendocrine differentiation.
*Adenocarcinoma with Paneth cell neuroendocrine differentiation.
*Carcinoid tumour of the prostate.
*[[Small cell carcinoma of the prostate gland]].
*Large cell neuroendocrine carcinoma of the prostate.
*Mixed (small and/or large cell) neuroendocrine carcinoma-acinar adenocarcinoma.

==IHC==
*[[PSA]] typically negative in NE carcinoma.

==See also==
*[[Prostate cancer]].
*[[Neuroendocrine carcinoma]].

==References==
{{Reflist|1}}

[[Category:Genitourinary pathology]]

← Older revision		Revision as of 22:47, 19 March 2018
Line 21:		Line 21:
	*[[Prostate cancer]].		*[[Prostate cancer]].
	*[[Neuroendocrine carcinoma]].		*[[Neuroendocrine carcinoma]].
			*[[Paneth cell-like change of the prostate gland]].

	==References==		==References==